
Chronic Lymphocytic Leukemia
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.














Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses updated findings from the DUO study in patients with chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, discusses the clinical implications of the DUO trial in patients with chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses the clinical implications of the MURANO trial and highlights the feasibility for time-limited therapy and its benefits for patients with chronic lymphocytic leukemia.








Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5























































